(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.
This study aims to understand how a new medication called nurandociguat interacts with nitroglycerin, a commonly used heart drug, in individuals who have coronary artery disease. Researchers want to find out if taking these two medicines together is safe and what effects they have on the body. This is an early-stage study, meaning it's one of the first steps to see how a new drug works in humans. The study is open to adults aged 18 and over, regardless of their gender. While the focus is on coronary artery disease, the study also considers people who may have chronic kidney disease.
At a glance
What is this study about?
This study is about a new medicine called nurandociguat. The researchers want to find out how it works when taken at the same time as a well-known heart medicine, nitroglycerin. Nitroglycerin is often used to help with chest pain (angina) in people with coronary artery disease, which is when the blood vessels supplying the heart become narrowed or blocked. The main goal is to make sure this new combination is safe and to see how it affects the body.
This is an early-stage study, sometimes called a Phase I study. This means it's one of the first times this new medicine, nurandociguat, is being tested in people. Early studies like this are very important because they help us understand if a new treatment is safe and how best to give it, before it can be studied in larger groups of people.
The researchers are particularly interested in people who have coronary artery disease. They are also considering people who have chronic kidney disease, as these conditions can sometimes go hand-in-hand. By carefully checking how the body reacts to these medicines, doctors can learn more about how to treat heart conditions safely and effectively in the future.
Key takeaways
- Tests a new drug (nurandociguat) with a common heart medicine (nitroglycerin).
- Focuses on people with coronary artery disease and chronic kidney disease.
- Aims to understand safety and body effects of the drug combination.
- Open to adults aged 18 and over, both men and women.
- This is an early-stage study, learning how the new drug works in humans.
Who may be eligible?
This study is open to adults who are 18 years old or older. Both men and women can take part.
You would need to have been diagnosed with coronary artery disease. The study is also looking at people who might have chronic kidney disease alongside their heart condition. The research team will review your health information to make sure the study is a good fit for you.
If you're interested, the study doctors will chat with you about your health history and do some checks to see if you meet all the specific requirements to join.
- Are you 18 years old or older?
- Do you have coronary artery disease?
- Are you willing to take a new study drug (nurandociguat) alongside nitroglycerin?
- Do you have chronic kidney disease (if applicable)?
- Are you able to attend study visits and follow instructions?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
The information provided does not detail the exact steps involved in taking part. However, in studies like this, participants typically attend several visits to a clinic or hospital. During these visits, you might have blood tests, heart checks (like an ECG), and other medical examinations to see how your body is reacting to the medicine. You would likely receive the study medication (nurandociguat and nitroglycerin) as instructed by the study team.
There might be a period of follow-up after taking the medication to monitor your health. The total time you would be involved in the study would be explained by the study team, but it could range from a few weeks to several months, depending on the study design. All procedures and the full length of the study would be thoroughly explained to you before you decide to take part.
Potential risks and benefits
Locations (2)
- —Germany
- —Bulgaria
Common questions
What is the main goal of this study?
The main goal is to check how safe a new drug called nurandociguat is when taken with nitroglycerin, and what effects this combination has on the body in people with heart artery disease.
Who can take part in this study?
Adults aged 18 or older, both men and women, who have coronary artery disease, can potentially take part. The study also includes people with chronic kidney disease.
What does 'coronary artery disease' mean?
It's a condition where the blood vessels that supply blood to your heart become narrowed or blocked, which can lead to chest pain or other heart problems.
What is nitroglycerin?
Nitroglycerin is a common medicine used to help treat chest pain (angina) in people with heart conditions by widening blood vessels.
Will I receive a new treatment?
Yes, you would receive the new medicine nurandociguat along with nitroglycerin. This study is about understanding how these two drugs work together.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.